$RESVERLOGIX CORP(RVXCF)$ Resverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion Privileges

Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2026. In connection with the extension, Hepalink's conversion privileges have been eliminated and the interest rate has been amended from 12% to 18% per annum, commencing on May 14, 2024. The amendment is subject to execution of definitive transaction documents, customary closing conditions and receipt of all necessary approvals including approval of the Toronto Stock Exchange.

"We are very pleased with, and appreciate, the two-year extension of the debenture and the elimination of the conversion privileges, and we look forward to Hepalink's continued support," stated Donald McCaffrey, President & CEO of Resverlogix.